Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal carcinomatosis: Systematic review of clinical and experimental evidence with special emphasis on ovarian cancer
Archives of Gynecology and Obstetrics | Jun 07, 2018
Tempfer C, et al. - Researchers investigated if intraperitoneal chemotherapy could be an alternative to systemic chemotherapy and cytoreductive surgery for patients with peritoneal carcinomatosis (PC). Via performing a systematic review of clinical and experimental evidence on the safety and efficacy of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with PC, they recognized PIPAC as feasible, safe, and effective. In patients with recurrent cancer and PC, PIPAC maintains quality of life. In women with ovarian cancer and PC, PIPAC is as evidence-based as any other treatment beyond the third line of systemic chemotherapy and can be recommended in this indication.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries